ixazomib proteasome inhibitor

Ixazomib Citrate (1201902-80-8) Ixazomib citrate is a proteasome inhibitor that acts by preventing cell growth in solid tumours. It is an anti-cancer agent that is used for treatment of multiple myeloma. Compared with bortezomib, Ixazomib citrate obtains higher pharmacokinetics, efficacy, and anticancer activity. Product Name: Ixazomib Citrate CAS No.: 1201902-80-8 Assay: 98% Specification: CP, EP, In-house, as required Molecular Formula: C20H23BCl2N2O9 Molecular Weight: 517

(R)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetate (179324-87-9) (aR,3aS,4S,6S,7aR)-hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate is used in the design and preparation of Ixazomib and Bortezomib. Product Name: (R)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetate CAS No.: 179324-87-9 Assay: 98% End Use: Ixazomib Molecular Formula: C17H29BF3NO4